Harrison Global Holdings (NASDAQ: BLMZ) Strikes Game-Changing Biotech Deal with Biotree Co., Ltd.

Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.

Why This Matters to Investors

• Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
• The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
• Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
• Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.

Strategic Synergy

This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.

Executive Insight

"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."

Enrique Vargas

Vargasfinancialinc@gmail.com

 More On Newsinterestcorp ::

•   Martha Maria Mendez-Baldwin, PhD: Leading Youth Development as Director of Counseling at LIU-Hudson Graduate Center
•   Ricardo Salinas Accused of Hiring Black Cube to Influence UK Legal Case in USD $115M Loan Dispute
•   China’s Top 3 Pad Mount Transformer Manufacturers -leading for Oil-Immersed - Dry-Type Distribution Transformers
•   Ravalli County Notary Cynthia Mealy Recognized as AGNP Credentialed Notary
•   Reliable Sourcing for HP Indigo Digital Label Printing Ink: Meet Wiseprint at Label Expo

(845) 288-0020